Levocetirizina Krka (Levocetirizine Dihydrochloride)

Levocetirizine Dihydrochloride is used to treat allergic conditions by selectively blocking peripheral H1 receptors, thereby mitigating histamine‑driven symptoms.

• Allergic rhinitis: Provides relief from sneezing, nasal congestion, itching, and watery discharge caused by seasonal or perennial allergens, improving daily comfort.
• Chronic idiopathic urticaria: Decreases the number and intensity of hives and associated itching, helping patients achieve better symptom control.

• Levocetirizine Dihydrochloride selectively binds to peripheral H1‑histamine receptors with high affinity, preventing histamine from activating the receptor cascade that leads to vasodilation, increased vascular permeability, and sensory nerve stimulation. By antagonizing these receptors without readily crossing the blood‑brain barrier, it reduces allergic inflammation and symptom generation while minimizing central nervous system effects typical of first‑generation antihistamines. Its rapid oral absorption and minimal metabolism allow effective plasma concentrations within an hour, sustaining antihistaminic activity throughout the dosing interval.

Levocetirizina Krka may cause adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild headache reported in some patients.
• Dry mouth: sensation of oral dryness.
• Drowsiness: occasional mild sedation, less frequent than first‑generation antihistamines.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue requiring immediate medical attention.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Anaphylaxis: rare systemic allergic reaction that can be life‑threatening.

Levocetirizina Krka should be used with caution in certain situations.

• Pregnancy: consult a healthcare provider; safety not established.
• Breastfeeding: may be excreted in milk; use only if benefits outweigh risks.
• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Elderly: monitor for increased sedation or dizziness.
• Avoid alcohol: concurrent use may enhance drowsiness.
• Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Levocetirizina Krka can interact with other substances; some require avoidance while others need monitoring.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase levocetirizine plasma levels, raising risk of side effects.
• Alcohol and other central nervous system depressants: can cause excessive drowsiness or sedation.

Moderate Interactions (Monitor Closely)

• Theophylline: may reduce antihistamine efficacy.
• Ritonavir: may elevate levocetirizine concentrations.
• Concurrent antihistamines: additive antihistaminic effect may increase risk of sedation.